Browsing Tag
Ferinject
2 posts
CSL (ASX: CSL) crashes 17.7% to A$98.59 after FY26 guidance cut and $5bn impairments
CSL cut FY26 NPATA to US$3.1 billion and flagged US$5 billion in impairments. The third downgrade in ten months is repricing the entire ASX healthcare sector.
May 11, 2026
American Regent’s HEART-FID trial for INJECTAFER fails to meet primary endpoint
American Regent, Inc., a subsidiary of Daiichi Sankyo Group, has announced disappointing results from its phase 3 HEART-FID…
August 27, 2023